Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2018 May 3

PMID 29718453

Citations 41

Authors

Jonathan M Loree

Ann M Bailey

Amber M Johnson

Yao Yu

Wenhui Wu

Christopher A Bristow

Jennifer S Davis

Kenna R Shaw

Russell Broaddus

Kimberly C Banks

Richard B Lanman

Funda Meric-Bernstam

Michael J Overman

Scott Kopetz

Kanwal Raghav

Affiliations

Soon will be listed here.

Abstract

Background: Despite growing therapeutic relevance of ERBB2 amplifications in colorectal cancer (CRC), little is known about ERBB2/ERBB3 mutations. We aimed to characterize these subsets of CRC.

Methods: We performed a retrospective analysis of 419 CRC patients from MD Anderson (MDACC) and 619 patients from the Nurses' Health Study (NHS)/Health Professionals Follow-Up Study (HPFS) with tissue sequencing, clinicopathologic, mutational, and consensus molecular subtype (CMS) profiles of ERBB2/ERBB3 mutant patients. A third cohort of 1623 CRC patients with ctDNA assays characterized the ctDNA profile of ERBB2 mutants. All statistical tests were two-sided.

Results: ERBB2 mutations occurred in 4.1% (95% confidence interval [CI] = 2.4% to 6.4%), 5.8% (95% CI = 4.1% to 8.0%), and 5.1% (95% CI = 4.0% to 6.2%) of MDACC, NHS/HPFS, and ctDNA patients, respectively. ERBB3 mutations occurred in 5.7% (95% CI = 3.7% to 8.4%, 95% CI = 4.0% to 7.8%) of patients in both tissue cohorts. Age, stage, and tumor location were not associated with either mutation. Microsatellite instability (MSI) was associated with ERBB2 (odds ratio [OR] = 5.98, 95% CI = 2.47 to 14.49, P < .001; OR = 5.13, 95% CI = 2.38 to 11.05, P < .001) and ERBB3 mutations (OR = 3.48, 95% CI = 1.51 to 8.02, P = .002; OR = 3.40, 95% CI = 1.05 to 10.96, P = .03) in both tissue cohorts. Neither gene was associated with TP53, APC, KRAS, NRAS, or BRAF mutations in tissue. However, PIK3CA mutations were strongly associated with ERBB2 mutations in all three cohorts (OR = 3.68, 95% CI = 1.83 to 7.41, P = .001; OR = 2.25, 95% CI = 1.11 to 4.58, P = .02; OR = 2.11, 95% CI = 1.25 to 3.58, P = .004) and ERBB3 mutations in the MDACC cohort (OR = 13.26, 95% CI = 5.27 to 33.33, P < .001). ERBB2 (P = 0.08) and ERBB3 (P = .008) mutations were associated with CMS1 subtype. ERBB2 (hazard ratio [HR] = 1.82, 95% CI = 1.23 to 4.03, P = .009), but not ERBB3 (HR = 0.88, 95% CI = 0.45 to 1.73, P = .73), mutations were associated with worse overall survival.

Conclusions: MSI and PIK3CA mutations are associated with ERBB2/ERBB3 mutations. Co-occurring PIK3CA mutations may represent a second hit to oncogenic signaling that needs consideration when targeting ERBB2/ERBB3.

Citing Articles

Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas.

Quaquarini E, Grillo F, Gervaso L, Arpa G, Fazio N, Vanoli A Cancers (Basel). 2024; 16(18).

PMID: 39335117 PMC: 11430748. DOI: 10.3390/cancers16183145.

HER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study.

El-Deek H, Hafez M, Sotouhy T, Mosad Zaki E, Eltyb H, Kamal F Asian Pac J Cancer Prev. 2024; 25(6):2023-2032.

PMID: 38918664 PMC: 11382861. DOI: 10.31557/APJCP.2024.25.6.2023.

Anti-Cancer Mechanisms of Diarylpentanoid MS17 (1,5-Bis(2-hydroxyphenyl)-1,4-pentadiene-3-one) in Human Colon Cancer Cells: A Proteomics Approach.

Hon K, Zainal Abidin S, Abas F, Othman I, Naidu R Int J Mol Sci. 2024; 25(6).

PMID: 38542474 PMC: 10970808. DOI: 10.3390/ijms25063503.

Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer.

Saoudi Gonzalez N, Ros J, Baraibar I, Salva F, Rodriguez-Castells M, Alcaraz A Cancers (Basel). 2024; 16(2).

PMID: 38254903 PMC: 10814823. DOI: 10.3390/cancers16020412.

PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room.

Raghav K, Loree J, Kopetz S Clin Cancer Res. 2023; 30(2):260-262.

PMID: 37975903 PMC: 10841812. DOI: 10.1158/1078-0432.CCR-23-2580.

References

Zuo W, Jiang Y, Wang Y, Xu X, Hu X, Liu G . Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer. Clin Cancer Res. 2016; 22(19):4859-4869. DOI: 10.1158/1078-0432.CCR-15-3036. View

Raghav K, Morris V, Tang C, Morelli P, Amin H, Chen K . MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016; 7(34):54627-54631. PMC: 5342368. DOI: 10.18632/oncotarget.10559. View

Majewski I, Nuciforo P, Mittempergher L, Bosma A, Eidtmann H, Holmes E . PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol. 2015; 33(12):1334-9. PMC: 5087318. DOI: 10.1200/JCO.2014.55.2158. View

Wen W, Chen W, Xiao N, Bender R, Ghazalpour A, Tan Z . Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers. J Mol Diagn. 2015; 17(5):487-95. PMC: 6136063. DOI: 10.1016/j.jmoldx.2015.04.003. View

Hechtman J, Zehir A, Yaeger R, Wang L, Middha S, Zheng T . Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Mol Cancer Res. 2015; 14(3):296-301. PMC: 4972456. DOI: 10.1158/1541-7786.MCR-15-0392-T. View

Kopetz S, Guthrie K, Morris V, Lenz H, Magliocco A, Maru D . Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2020; 39(4):285-294. PMC: 8462593. DOI: 10.1200/JCO.20.01994. View

Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies M . Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015; 33(25):2753-62. PMC: 4550690. DOI: 10.1200/JCO.2014.60.4165. View

Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang L . Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015; 61(3):544-53. PMC: 4511273. DOI: 10.1373/clinchem.2014.231100. View

Malapelle U, Pisapia P, Sgariglia R, Vigliar E, Biglietto M, Carlomagno C . Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. J Clin Pathol. 2016; 69(9):767-71. PMC: 5036215. DOI: 10.1136/jclinpath-2015-203403. View

10.

Choi M, An C, Chung Y, Choi Y, Yoo N, Lee S . Mutational and expressional analysis of ERBB3 gene in common solid cancers. APMIS. 2014; 122(12):1207-12. DOI: 10.1111/apm.12286. View

11.

Lee J, Soung Y, Seo S, Kim S, Park C, Wang Y . Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res. 2006; 12(1):57-61. DOI: 10.1158/1078-0432.CCR-05-0976. View

12.

Loree J, Kopetz S, Raghav K . Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. J Gastrointest Oncol. 2017; 8(1):199-212. PMC: 5334060. DOI: 10.21037/jgo.2017.01.01. View

13.

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C . A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2012; 1(6):508-23. DOI: 10.1158/2159-8290.CD-11-0109. View

14.

Strickler J, Loree J, Ahronian L, Parikh A, Niedzwiecki D, Pereira A . Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discov. 2017; 8(2):164-173. PMC: 5809260. DOI: 10.1158/2159-8290.CD-17-1009. View

15.

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F . Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016; 17(6):738-746. DOI: 10.1016/S1470-2045(16)00150-9. View

16.

Kavuri S, Jain N, Galimi F, Cottino F, Leto S, Migliardi G . HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 2015; 5(8):832-41. PMC: 4527087. DOI: 10.1158/2159-8290.CD-14-1211. View

17.

Rosty C, Young J, Walsh M, Clendenning M, Sanderson K, Walters R . PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One. 2013; 8(6):e65479. PMC: 3681782. DOI: 10.1371/journal.pone.0065479. View

18.

. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-7. PMC: 3401966. DOI: 10.1038/nature11252. View

19.

Hyman D, Piha-Paul S, Won H, Rodon J, Saura C, Shapiro G . HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018; 554(7691):189-194. PMC: 5808581. DOI: 10.1038/nature25475. View

20.

Richman S, Southward K, Chambers P, Cross D, Barrett J, Hemmings G . HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2015; 238(4):562-70. PMC: 4785607. DOI: 10.1002/path.4679. View